WCG opens new office in Tokyo, Japan

According to the WCG (WIRB-Copernicus Group), the new offices in the Asia-Pacific region bolster its ability to support “increasingly complex, global clinical trials." ​Notably, ​in the areas of drug and diagnostic development for oncology and central nervous system (CNS) diseases.

"By expanding WCG's footprint abroad, we are helping to ensure that every trial— especially the most complicated and challenging ones—can benefit from our latest advances in trial optimization, signal detection and patient recruitment,” ​said Donald A. Deieso, PhD, chairman and CEO of WCG in a press release.

As Deieso explained, the Tokyo office will house the company’s clinical services division in Asia, as well as a center of excellence for its “growing”​ patient engagement group.

Earlier this year​, WCG expanded its clinical services division to include the endpoint adjudication and data monitoring services with the acquisition of ACI Clinical.

The purchase – announced in March – followed a series of acquisitions made over the last year in areas such as patient recruitment, electronic consent (eConsent), and pharmacovigilance.